Cargando…

Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers

INTRODUCTION: Endocrine therapy of breast cancer, which either deprives cancer tissue of estrogen or prevents estrogen pathway signaling, is the most common treatment after surgery and radiotherapy. We have previously shown for the estrogen-responsive MCF-7 cell line that exposure to tamoxifen, or d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leung, Euphemia Y., Askarian-Amiri, Marjan E., Sarkar, Debina, Ferraro-Peyret, Carole, Joseph, Wayne R., Finlay, Graeme J., Baguley, Bruce C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591432/ https://www.ncbi.nlm.nih.gov/pubmed/28929082 http://dx.doi.org/10.3389/fonc.2017.00184

Ejemplares similares

Epigenetic regulation in human melanoma: past and future
por: Sarkar, Debina, et al.
Publicado: (2015)

Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations
por: Leung, Euphemia Y., et al.
Publicado: (2018)

Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing
por: Sarkar, Debina, et al.
Publicado: (2017)

Correction: Sarkar, D., et al. Multiple Isoforms of ANRIL in Melanoma Cells: Structural Complexity Suggests Variations in Processing. Int. J. Mol. Sci. 2017, 18, 1378
por: Sarkar, Debina, et al.
Publicado: (2018)

Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population
por: Leung, Euphemia, et al.
Publicado: (2014)

Heterogeneity of expression of epithelial–mesenchymal transition markers in melanocytes and melanoma cell lines
por: Kim, Ji Eun, et al.
Publicado: (2013)

Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs
por: Leung, Euphemia Yee, et al.
Publicado: (2014)

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines
por: Leung, Euphemia Y., et al.
Publicado: (2015)

Keeping abreast with long non-coding RNAs in mammary gland development and breast cancer
por: Hansji, Herah, et al.
Publicado: (2014)

ZFAS1: a long noncoding RNA associated with ribosomes in breast cancer cells
por: Hansji, Herah, et al.
Publicado: (2016)

Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines
por: Leung, Euphemia Y., et al.
Publicado: (2014)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Emerging Role of Long Non-Coding RNA SOX2OT in SOX2 Regulation in Breast Cancer
por: Askarian-Amiri, Marjan E., et al.
Publicado: (2014)

Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival
por: D’mello, Stacey Ann N., et al.
Publicado: (2014)

Signaling Pathways in Melanogenesis
por: D’Mello, Stacey A. N., et al.
Publicado: (2016)

The Role of the Hippo Pathway in Melanocytes and Melanoma
por: Kim, Ji Eun, et al.
Publicado: (2013)

Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines
por: Kim, Ji Eun, et al.
Publicado: (2012)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
por: Xu, Jing, et al.
Publicado: (2023)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Prognostic Relevance of Estrogen Receptor Status in Circulating Tumor Cells in Breast Cancer Patients Treated With Endocrine Therapy
por: Zhou, Ying, et al.
Publicado: (2022)

Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells
por: Leung, Euphemia, et al.
Publicado: (2011)

ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor–Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy
por: Reinert, Tomás, et al.
Publicado: (2020)

In Vitro Analysis of Breast Cancer Cell Line Tumourspheres and Primary Human Breast Epithelia Mammospheres Demonstrates Inter- and Intrasphere Heterogeneity
por: Smart, Chanel E., et al.
Publicado: (2013)

Correction: In Vitro Analysis of Breast Cancer Cell Line Tumourspheres and Primary Human Breast Epithelia Mammospheres Demonstrates Inter- and Intrasphere Heterogeneity
por: Smart, Chanel E., et al.
Publicado: (2013)

In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
por: Cheng, Gary J., et al.
Publicado: (2022)

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
por: Datta, Jharna, et al.
Publicado: (2022)

Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice
por: Baguley, Bruce C., et al.
Publicado: (2014)

Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
por: Sweetlove, Melanie, et al.
Publicado: (2015)

Signal Pathway of Estrogen and Estrogen Receptor in the Development of Thyroid Cancer
por: Liu, Jian, et al.
Publicado: (2021)

Variable Expression of GLIPR1 Correlates with Invasive Potential in Melanoma Cells
por: Awasthi, Anshul, et al.
Publicado: (2013)

Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes
por: Lizcano, Fernando
Publicado: (2022)

Metabolic Adaptations in an Endocrine-Related Breast Cancer Mouse Model Unveil Potential Markers of Tumor Response to Hormonal Therapy
por: Araújo, Rita, et al.
Publicado: (2022)

MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a “Genetic Switch” Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma
por: Eccles, Michael R., et al.
Publicado: (2013)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
por: Gwark, Sungchan, et al.
Publicado: (2021)

ENDOCRINE DISRUPTORS: Estrogens in a Bottle?
por: Barrett, Julia R.
Publicado: (2009)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

DNA-Binding Anticancer Drugs: One Target, Two Actions
por: Baguley, Bruce C., et al.
Publicado: (2021)

Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance
por: Bellerby, Rebecca, et al.
Publicado: (2016)

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o0ffin4am7b933r9v8im5n25ln